7th Annual Live Medical Crossfire®: Hematologic Malignancies
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Addressing Clinical Gaps in Thyroid Cancer Management: Taking Action with Precision Methods to Personalize Treatment Decision-Making
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
Evolving Evidence in Pediatric Brain Cancer: Spotlight on MAPK Inhibitors
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung CancerJune 5th 2023
The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.
Cilta-cel Possesses Potential to Be New SOC for Lenalidomide-refractory Myeloma After First Relapse
Ciltacabtagene autoleucel significantly improved progression-free survival over standard-of-care pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Fruquintinib/BSC Demonstrates OS/PFS Benefit in Refractory mCRC, Irrespective of Prior Treatment
Treatment with fruquintinib plus best supportive care led to improved overall survival and progression-free survival vs placebo plus best supportive care in patients with refractory metastatic colorectal cancer, irrespective of number of prior lines of therapy or type of prior treatment.
Lasofoxifene/Abemaciclib Shows Clinically Meaningful Efficacy in ER+/HER2- ESR1-Mutant Breast CancerJune 5th 2023
Longer follow-up data from the phase 2 ELAINE-2 study demonstrated that treatment with lasofoxifene and abemaciclib resulted in clinically meaningful antitumor activity as well as continued tolerability with no new safety signals for patients with estrogen receptor-positive HER2-negative ESR1-mutated breast cancer who previously received CDK4/6 inhibitors.
Doxorubicin/Zalifrelimab/Balstilimab Generates Activity in Soft Tissue SarcomaJune 5th 2023
Treatment with doxorubicin plus zalifrelimab and balstilimab produced a favorable 6-month progression-free survival rate in patients with difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy.
TAS-102 Plus Bevacizumab Fails to Extend OS in Unresectable mCRCJune 5th 2023
The combination of trifluridine/tipiracil and bevacizumab did not demonstrate a significant overall survival benefit vs capecitabine plus bevacizumab in patients with unresectable, metastatic colorectal cancer ineligible for intensive chemotherapy.
Lenvatinib Plus Pembrolizumab Maintains Survival Benefit in Advanced RCCJune 5th 2023
Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBCJune 5th 2023
Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.
Enfortumab Vedotin Plus Pembrolizumab Produces Durable Responses, Safety in Metastatic Urothelial CarcinomaJune 5th 2023
The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
Cabozantinib Plus Nivolumab/Ipilimumab Improves PFS, DCR in Metastatic Soft Tissue SarcomaJune 5th 2023
The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma.
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal MelanomaJune 5th 2023
The protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 demonstrated preliminary antitumor activity and acceptable safety for patients with recurrent high-grade glioma and advanced or metastatic uveal melanoma, according to data from the dose-expansion portion of a phase 1 trial presented at the 2023 ASCO Annual Meeting.
Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic OncologyJune 5th 2023
Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial CancerJune 5th 2023
Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLCJune 5th 2023
Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.
Trastuzumab Deruxtecan Elicits Responses in Difficult-To-Treat HER2+ Solid Tumors
Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.
Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast CancerJune 5th 2023
The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.
Tovorafenib Presents Opportunity for Tumor Reduction in Pediatric Low-Grade GliomaJune 4th 2023
Treatment with tovorafenib elicited encouraging and fast onset responses in heavily pretreated pediatric patients with low-grade glioma regardless of response assessment criteria, according to data from the phase 2 FIREFLY trial that were presented at the 2023 ASCO Annual Meeting.
Benefits of Neoadjuvant Nivolumab/Chemo Elucidated in NSCLC Exploratory AnalysisJune 4th 2023
Neoadjuvant nivolumab plus chemotherapy improved clinical outcomes vs chemotherapy alone in patients with resectable non–small cell lung cancer who received definitive surgery with numerical but not statistical improvements seen even when definitive surgery was not achieved.
Nirogacestat Provides Rapid and Sustained Pain Reduction for Patients With Desmoid TumorsJune 4th 2023
Treatment with the investigational gamma secretase inhibitor nirogacestat allowed patients with progressing desmoid tumors to experience a significant and clinically meaningful reduction in several aspects of disease-related pain when compared with placebo.
Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast CancerJune 4th 2023
Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.
TIGIT, PD-1 Bispecific Rilvegostomig Shows Promise Following Prior Immunotherapy Resistance for Advanced PD-L1+ NSCLCJune 4th 2023
The PD-1 and TIGIT bispecific rilvegostomig demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer following progression on at least 1 prior checkpoint inhibitor. according to initial findings from the phase 1/2 ARTEMIDE-01 study.
Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPCJune 4th 2023
The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPCJune 4th 2023
Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.